IRIS UniCatt

Baranello, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.118
EU - Europa 2.925
AS - Asia 2.416
SA - Sud America 460
AF - Africa 68
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 8.996
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.010
DE - Germania 1.189
SG - Singapore 1.120
CN - Cina 591
BR - Brasile 369
NL - Olanda 366
SE - Svezia 269
IT - Italia 259
FR - Francia 208
VN - Vietnam 173
GB - Regno Unito 139
UA - Ucraina 102
IE - Irlanda 99
IN - India 92
JP - Giappone 76
ID - Indonesia 67
FI - Finlandia 64
BD - Bangladesh 62
RU - Federazione Russa 58
CA - Canada 53
HK - Hong Kong 51
PL - Polonia 39
AR - Argentina 36
KR - Corea 36
IQ - Iraq 30
TR - Turchia 30
MX - Messico 29
BE - Belgio 23
AT - Austria 17
EC - Ecuador 16
ZA - Sudafrica 16
ES - Italia 14
CH - Svizzera 12
EG - Egitto 12
MK - Macedonia 12
RS - Serbia 12
CO - Colombia 11
PK - Pakistan 11
MA - Marocco 9
VE - Venezuela 9
LT - Lituania 8
TN - Tunisia 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 7
CZ - Repubblica Ceca 7
PA - Panama 7
PE - Perù 7
PH - Filippine 7
SA - Arabia Saudita 7
CI - Costa d'Avorio 6
CL - Cile 6
IL - Israele 6
MY - Malesia 6
IR - Iran 5
AU - Australia 4
GT - Guatemala 4
JO - Giordania 4
KE - Kenya 4
NP - Nepal 4
PY - Paraguay 4
TH - Thailandia 4
BG - Bulgaria 3
CR - Costa Rica 3
DK - Danimarca 3
DZ - Algeria 3
LV - Lettonia 3
SN - Senegal 3
TW - Taiwan 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GR - Grecia 2
KG - Kirghizistan 2
LU - Lussemburgo 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PS - Palestinian Territory 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BO - Bolivia 1
CG - Congo 1
CY - Cipro 1
HR - Croazia 1
HT - Haiti 1
JM - Giamaica 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
Totale 8.985
Salva come PNG Salva come JPEG
Città #
Singapore 667
Amsterdam 352
Ashburn 343
San Jose 327
Chandler 316
New York 158
Frankfurt am Main 154
Hefei 106
Los Angeles 104
Beijing 103
Dublin 82
Tokyo 76
Jacksonville 68
Munich 63
Ho Chi Minh City 62
Jakarta 61
Lauterbourg 61
Ann Arbor 55
Dallas 55
Rome 50
Hong Kong 49
Chicago 48
San Mateo 47
São Paulo 47
Hanoi 46
Milan 46
Nürnberg 40
Marseille 39
Dearborn 38
Seattle 38
Boston 37
Tukwila 36
Wilmington 36
Seoul 35
Nanjing 34
Buffalo 30
Houston 29
Moscow 29
Santa Clara 28
The Dalles 26
Kent 25
Warsaw 25
Council Bluffs 24
Montreal 24
Atlanta 22
Boardman 21
Woodbridge 21
Brooklyn 20
Brussels 20
London 20
Princeton 20
Denver 19
Helsinki 19
Orem 19
Fairfield 18
Lancaster 18
Paris 18
Turku 18
Bremen 17
Chennai 17
Nuremberg 17
Nanchang 16
Poplar 15
Palermo 14
Rio de Janeiro 14
Stockholm 14
Augusta 13
Baghdad 13
Hangzhou 13
Johannesburg 13
Mexico City 13
Düsseldorf 12
Lawrence 12
Pune 12
Phoenix 11
Leawood 10
Redwood City 10
San Francisco 10
Skopje 10
Changsha 9
Norwalk 9
Toronto 9
Haiphong 8
Hebei 8
Manchester 8
Mumbai 8
Secaucus 8
Shanghai 8
Vienna 8
Washington 8
Ankara 7
Belo Horizonte 7
Brasília 7
Cairo 7
Dhaka 7
Jinan 7
Lappeenranta 7
Lima 7
Memphis 7
Portsmouth 7
Totale 4.829
Salva come PNG Salva come JPEG
Nome #
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 681
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 503
Cortical visual function in preterm infants in the first year. 276
Prognostic value of EEG performed at term age in preterm infants. 230
Neurological examination at 6 to 9 months in infants with cystic periventricular leukomalacia 226
-Thalamic atrophy in infants with PVL and cerebral visual impairment 205
External hydrocephalus in discordant birth weight twins: a case report 184
Sleep disturbances in preschool age children with cerebral palsy: a questionnaire study 183
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 181
Visual development in prenatal post-haemorragic ventricular dilatation 180
Early development in Dravet syndrome; visual function impairment precedes cognitive decline 171
Sleep disturbances in preschool age children with cerebral palsy: a questionnaire study 167
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 165
Antenatal post-hemorragic ventriculomegaly: a prospective follow-up study 164
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 161
Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol 158
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 157
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 156
Visual processing in Noonan syndrome: dorsal and ventral stream sensitivity 156
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 156
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 149
Visual processing in Noonan syndrome: dorsal and ventral stream sensitivity 149
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy 148
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. 145
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants 142
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 139
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 135
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 135
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 134
6 minute walk test in duchenne MD patients with different mutations:12 month changes 134
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 133
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 133
antenatal post hemorrhagic ventriculomegaly: a prospective follow up study 129
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 128
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 124
The emerging spectrum of neurodevelopmental comorbidities in early-onset Spinal Muscular Atrophy 122
Genetic modifiers of upper limb function in Duchenne muscular dystrophy 121
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 117
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study 117
Development of an International SMA Bulbar Assessment for Inter-professional Administration 116
Longitudinal natural history in young boys with Duchenne muscular dystrophy 113
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 110
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy 110
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 110
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 107
Risdiplam in Type 1 Spinal Muscular Atrophy 105
Implicit learning deficit in children with Duchenne muscular dystrophy: Evidence for a cerebellar cognitive impairment? 104
Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA) 99
Registries versus tertiary care centers: How do we measure standards of care in Duchenne muscular dystrophy? 95
Longitudinal data of neuropsychological profile in a cohort of Duchenne muscular dystrophy boys without cognitive impairment 92
null 81
Erratum: Long term natural history data in ambulant boys with duchenne muscular dystrophy: 36-month changes (PLoS ONE (2015) 10:12 (e0144079)) 77
Genetic modifiers of respiratory function in Duchenne muscular dystrophy 77
Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53 (PLoS ONE (2019) 14:6 (e0218683) DOI: 10.1371/journal.pone.0218683) 77
Cognitive profile in Duchenne muscular dystrophy boys without intellectual disability: The role of executive functions 76
Severe abnormalities of the pons in two infants with Goldenhar syndrome 74
Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: Critical issues and areas for improvements 73
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 64
null 64
The neurological examination of the newborn baby 63
Visual findings in infants with periventricular leukomalacia: 139 54
Visual development in infants with prenatal posthaemorrhagic ventricular dilatation 53
1st Italian SMA Family Association Consensus Meeting: Management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I-III, Rome, Italy, 30-31 January 2015 34
1st Italian SMA Family Association Consensus Meeting: Management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I-III, Rome, Italy, 30-31 January 2015 32
Loss of ambulation in SMA III at the time of disease-modifying treatments: an international study 10
Neurodevelopmental and mental disorders in children with type I and presymptomatic spinal muscular atrophy 6
Refining functional phenotypes in an international cohort of untreated paediatric type 2 and 3 SMA patients using the Revised Hammersmith Scale 5
Expressive language and social communication abilities in children with spinal muscular atrophy type 1 2
Totale 9.077
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.231
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.231
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213 0 0 0 0 0 0 0 0 0 0 0 3
2021/2022384 19 17 19 41 25 15 7 64 29 23 61 64
2022/2023978 104 126 63 146 59 113 49 83 145 22 44 24
2023/2024635 36 131 20 40 25 134 61 18 5 23 63 79
2024/20251.373 24 26 99 45 123 73 53 56 176 109 326 263
2025/20264.458 464 115 256 466 748 946 544 179 222 224 171 123
Totale 9.077